CardiNor AS is a Norwegian biotech company to handle the commercialization of secretoneurin, a new biomarker for cardiovascular disease.
Our innovation is a novel and proprietary cardiac biomarker test – secretoneurin. Secretoneurin is shown to have strong prognostic value in patients with heart failure and it holds a paramount potential in patients with heart disease with arrhythmia that may require cardiac rhythm management.
Cardiovascular disease is the leading cause of morbidity and mortality in the world. However, none of the current cardiac biomarkers in use play a role in decision-making concerning medical and surgical interventions to prevent life-threatening cardiac arrhythmias.
The company is currently developing an easy to use research use test that it will market and sell through a network of local distributors covering than major markets in Europe and the US, followed by the introduction a CE marked product and later seek regulatory approval in the US.
The CardiNor management team have in-depth knowledge of, and experience from biotech and diagnostic industry covering complete life cycle activities from start-up to exit. CardiNor AS is collaborating with world leading academic institutions and industry in developing and documenting its proprietary novel biomarker test.